TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05779709

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Reformer pilates is a specific type that provides resistance exercise at certain weights with the pulley system relying basically on the same principles. Pilates exercises provide breathing and activation of the deep stabilizing muscles of the trunk in coordination with the PFMs. It includes exercises that focus on pelvic stability, mobility and body alignment. PFMs activation is carried out simultaneously with the trunk muscles in various positions in coordination with breathing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urotherapy
Description: Urotherapy includes education of the child and family, diet (adequate fiber and fluid consumption), regular optimal voiding, daily physical activity, teaching normal toilet use, pelvic floor muscle training and relaxation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urotherapy
Description: Urotherapy includes education of the child and family, diet (adequate fiber and fluid consumption), regular optimal voiding, daily physical activity, teaching normal toilet use, pelvic floor muscle training and relaxation
Study: NCT06120257

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lithotripsy using Flexible ureteroscope
Description: using Flexible ureteroscope and holmium laser lithotripsy to get high stone clearance rate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shock wave lithotripsy (ESWL)
Description: using extracorporeal shock wave lithotripsy (ESWL) to get high stone clearance rate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: holmium laser lithotripsy using Karl® Storz MIP set
Description: using holmium laser lithotripsy using Karl® Storz MIP set to get high stone clearance rate
Study: NCT04671836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam 1Mg Tablet
Description: 1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam 1Mg Tablet
Description: 1 mg, white, five-sided (shield shape) tablet with a raised A on one side and BPI and 64 impressed on scored reverse side. NDC 0187-0064-01 - Bottles of 100 tablets; NDC 0187-0064-50 - Bottles of 500 tablets; NDC 0187-0064-10 - Bottles of 1000 tablets.~The pharmacy at the Zucker Hillside Hospital will encapsulate both lorazepam 1 mg and placebo pills to make them look the same. On the day of the scan, the research coordinator or the PI will pick up the blinded study medication (lorazepam or placebo) and will administer it to the participant. One hour later, the participant will be placed in the scanner to complete the MRI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be purchased and encapsulated by the pharmacy at the Zucker Hillside Hospital.
Study: NCT05043584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluobeam LX, Fluoptics, Grenoble, France
Description: See arm description
Study: NCT05671276

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin and clopidogrel
Description: DAPT (until 6 months) + ASA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: half-dose NOAC
Study: NCT05415748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tamsulosin and matching placebo to be taken in a randomized order for 12 weeks
Study: NCT06261671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antioxidants-enriched culture medium (Gx)
Description: Blastocyst will be in continuous culture conditions (parallel antioxidants-enriched culture medium (Gx) and Global total one step media (GT) without refreshment on day 3. A refreshment of the media will be done on D5 in both groups.
Study: NCT06131502

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy
Description: The ExAblate transcranial system combines a focused ultrasound surgery delivery system and a conventional diagnostic 3T MRI scanner. The ExAblate transcranial system provides real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: ExAblate MR-guided Focused Ultrasound Bilateral Anterior Capsulotomy
Description: The ExAblate transcranial system combines a focused ultrasound surgery delivery system and a conventional diagnostic 3T MRI scanner. The ExAblate transcranial system provides real-time therapy planning algorithm, thermal dosimetry, and closed-loop therapy control.
Study: NCT05513742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTX-009
Description: IV infusion administered on day 1 and 15 of every 28-day cycle
Study: NCT06248853

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garston technique
Description: the patients will receive instrumented assisted soft tissue mobilization using the Graston technique, which includes the application of a cream to the posterior calf and plantar foot from the knee to the toes to reduce friction on the skin. The Graston tools will be used to mobilize the tissues of the triceps surae and plantar foot bypassing the tools along the leg and foot

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: the patients will receive pedaling an exercise bicycle for 5 min with minimal resistance to warm the tissues, gastrocnemius stretches performed on a step for three repetitions held for 30 sec each , plantar fascia stretching performed in a seated position for three repetitions held for 30 sec each, and foot intrinsic muscular strengthening using a short foot exercise. Ice will be offered as needed for pain management after each session in addition to home program exercise
Study: NCT05095025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride 20ml injectate
Description: Sequential dosing, starting at 50mg with 5mg increments based on the outcome of the preceding participant
Study: NCT05279079

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of accuracy of microRNA and pancreatic enzyme markers in blood and/or urine in the detection and/or prediction of severity of drug-associated acute pancreatitis
Description: Panel of microRNA and pancreatic enzyme biomarkers

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of accuracy of microRNA and pancreatic enzyme markers in blood and/or urine in the detection and/or prediction of severity of drug-associated acute pancreatitis
Description: Panel of microRNA and pancreatic enzyme biomarkers
Study: NCT05295537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PERCUTANEOUS LIVER BIOPSY (PLB)
Description: Percutaneous liver biopsy using a 16 gauge (G) Trucut needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENDOSCOPIC ULTRASOUND GUIDED LIVER BIOPSY (EUS-LB)
Description: EUS-guided liver biopsy using a 19 gauge (G) Franseen core EUS needle
Study: NCT05279079

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of accuracy of microRNA and pancreatic enzyme markers in blood and/or urine in the detection and/or prediction of severity of drug-associated acute pancreatitis
Description: Panel of microRNA and pancreatic enzyme biomarkers
Study: NCT06248853

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: the patients will receive pedaling an exercise bicycle for 5 min with minimal resistance to warm the tissues, gastrocnemius stretches performed on a step for three repetitions held for 30 sec each , plantar fascia stretching performed in a seated position for three repetitions held for 30 sec each, and foot intrinsic muscular strengthening using a short foot exercise. Ice will be offered as needed for pain management after each session in addition to home program exercise
Study: NCT05735639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin Sodium
Description: Low molecular weight heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin Sodium
Description: Low molecular weight heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin Sodium
Description: Low molecular weight heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin Sodium
Description: Low molecular weight heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Sodium
Description: Low molecular weight heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Sodium
Description: Low molecular weight heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Direct oral anticoagulant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Direct oral anticoagulant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: Direct oral anticoagulant
Study: NCT05652725

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 1.1 Usage
Description: Participants will use their Radicle Clarity Active Study Product 1.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 2.1 Usage
Description: Participants will use their Radicle Clarity Active Study Product 2.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 3.1 Usage
Description: Participants will use their Radicle Clarity Active Study Product 3.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 4.1 Usage
Description: Participants will use their Radicle Clarity Active Study Product 4.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 4.2 Usage
Description: Participants will use their Radicle Clarity Active Study Product 4.2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 4.3 Usage
Description: Participants will use their Radicle Clarity Active Study Product 4.3 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 1
Description: Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 2
Description: Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 3
Description: Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 4
Description: Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 5
Description: Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 5.1 Usage
Description: Participants will use their Radicle Clarity Active Study Product 5.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Clarity Active Study Product 5.2 Usage
Description: Participants will use their Radicle Clarity Active Study Product 5.2 as directed for a period of 6 weeks.
Study: NCT04969757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Predigraft group
Description: Patients in the interventional arm will use Predigraft (Class 1 medical device under MDD 93/42/EEC Cibiltech Society) to receive therapeutic education content (videos, facts sheets, short messages, questionnaires), exchange documents with their doctors and interact via messaging with them.~Physicians will be able to calculate their iBox score to predict their patients' allograft survival at 3, 5 and 7 years.
Study: NCT05847205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-Hirudin
Description: 100 Patients will be treated with r-Hirudin (Thrombexx) for a total of 15 days beginning with 15 mg BID s.c starting 6 hours after surgery or upon adequate hemostasis and continued until end of study.
Study: NCT05350137

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 100% oxygen
Description: During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. Improved inflation-deflation method is currently the most widely used method in clinical practice. After dividing all the targeted vascular and bronchial structures, the lung of the operating side was re-inflated with 100% oxygen. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide
Description: During one-lung ventilation with an open chest, the non-ventilated lung collapses initially due to the inherent elastic recoil properties of the lung. Once passive venting has ceased, further collapse will then be wholly dependent on ongoing gaseous uptake and absorption atelectasis. The solubility coefficient for carbon dioxide is 0.57. The rapid diffusion properties of carbon dioxide would be expected to speed lung collapse and so facilitate surgery. After the targeted segment structures were successfully dissected, the collapsed intraoperative lung was completely re-expanded with carbon dioxide. After the operative lungs is completely expanded, perform pure oxygen mechanical single lung ventilation for the healthy lung, waiting for clear presentation of the plane between the targeted segment and the other segments.
Study: NCT02778165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyCaRe (my cardiac recovery Android application)
Description: Android application \& Fitbit Inspire 2 activity monitor
Study: NCT06323876

Intervention type: DIAGNOSTIC_TEST
Intervention: HRCT
Description: High resolution computed tomography (HRCT) scan is a medical imaging technique used to obtain detailed internal images of the body. HRCT images will be obtained at 0 and 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: HRCT
Description: High resolution computed tomography (HRCT) scan is a medical imaging technique used to obtain detailed internal images of the body. HRCT images will be obtained at 0 and 12 months.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: During blood draw, someone uses a needle to take blood from a vein, usually in your arm.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: During blood draw, someone uses a needle to take blood from a vein, usually in your arm.
Study: NCT05878730

Intervention type: DIAGNOSTIC_TEST
Intervention: urine collection
Description: * Urine collection will be made on a 12 hours period (20h00-8h00), the night before V2~* at V2 : 2 mL urinal sample for measure of 6-SMT concentration (ng/mL) and creatinin (mg/mL)~* Measure of 6-SMT will be made by a validated radio-immunology assay

Intervention type: DIAGNOSTIC_TEST
Intervention: urine collection
Description: * Urine collection will be made on a 12 hours period (20h00-8h00), the night before V2~* at V2 : 2 mL urinal sample for measure of 6-SMT concentration (ng/mL) and creatinin (mg/mL)~* Measure of 6-SMT will be made by a validated radio-immunology assay

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of Proteins
Description: * blood sample at V2 (2x3.5mL citrate tubes)~* measured by ELISA
Study: NCT05878730

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of Proteins
Description: * blood sample at V2 (2x3.5mL citrate tubes)~* measured by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of mRNA and miRNA
Description: * blood sample at V2 (2x2.5mL PAX-gene tube)~* measured by quantitative RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of mRNA and miRNA
Description: * blood sample at V2 (2x2.5mL PAX-gene tube)~* measured by quantitative RT-PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of plasmatic and intraerythrocytic lithium
Description: * blood sample at V2 (mmol/L)~* 4mL EDTA tube

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of plasmatic and intraerythrocytic lithium
Description: * blood sample at V2 (mmol/L)~* 4mL EDTA tube
Study: NCT06302530

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stayer
Description: In group A, the intervention involves using the Strayer technique, an echo-guided recession of the gastrocnemius tendon, with local anesthesia and sedation as needed. The patient can be in a prone or supine position. Ultrasound will identify the sural nerve and blood vessels to prevent damage. The entry point is 2-3 cm distal to the medial head of the gastrocnemius. Local anesthetic is infiltrated, and blunt dissection creates a working space. V-shaped curettes widen the entry point without harming noble structures.~Under direct ultrasound control, a curved scalpel is inserted until reaching the medial border of the gastrocnemius tendon. Transection occurs progressively from medial to lateral while flexing the foot. Verification of complete tendon transection is done with a blunt dissector. Finally, a dressing with adhesive strips and an elastic bandage is applied, eliminating the need for sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plantar transection
Description: In group B, an echo-guided transection of the plantar tendon will be performed. Local anesthesia and sedation will be used as needed. The patient will be in prone or supine position. The plantar tendon will be identified ultrasonographically on the medial aspect of the gastrocnemius distal to the myotendinous junction. Local anesthetic will be infiltrated at that point to isolate the plantar tendon. An ultrasound-guided retrograde hook is introduced until the plantar tendon is engaged. Then proceed to retrograde transection of the tendon from lateral to medial, verifying complete section. At the end, a dressing with adhesive strips and elastic bandage, without sutures, will be performed.
Study: NCT05275179

Intervention type: OTHER
Intervention: Posaconazole Therapeutic Drug Monitoring
Description: Therapeutic Drug Monitoring is performed by measuring posaconazole concentrations in serum on seven consecutive days (anticipated).
Study: NCT04953234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L
Description: Patients receive continuous TTFields treatment using the NovoTTF-100L device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
Study: NCT04860804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and Ketamine
Description: Drug: Proprietary oral formulation of 0.5mg/kg of ketamine + 324mg of aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ketamine
Description: Proprietary oral formulation of 0.5mg/kg of ketamine
Study: NCT06436638

Intervention type: DEVICE
Intervention: Non-invasive ventilation support equipment
Description: Non-invasive ventilation support is provided by nasal airway and nasal CPAP mask to avoid respiratory complications such as hypoxia, desaturation, hypercarbia, respiratory depression etc. during extraction of impacted molars under deep sedation.

Intervention type: DEVICE
Intervention: Non-invasive ventilation support equipment
Description: Non-invasive ventilation support is provided by nasal airway and nasal CPAP mask to avoid respiratory complications such as hypoxia, desaturation, hypercarbia, respiratory depression etc. during extraction of impacted molars under deep sedation.
Study: NCT05865691

Intervention type: OTHER
Intervention: biomarker assay
Description: blood sample on the day of inclusion

Intervention type: OTHER
Intervention: biomarker assay
Description: blood sample on the day of inclusion
Study: NCT04385173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B7-H3 CAR-T
Description: The B7-H3 CAR-T will be administrated via intratumoral or Intracerebroventricular injection through an Ommaya catheter in between Temozolomide cycles. Temozolomide will be stopped during the infusion of B7-H3 CAR-T

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide will be given to patients orally every 5 days with 23 days interval. The initial dose is 150 mg/m2 on the first day and 200 mg/m2 for the rest if no toxicity is seen. If 200 mg/m2 is toxic, the drug will return to 150 mg/m2 or will be stopped.